58 related articles for article (PubMed ID: 18617577)
21. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
22. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
24. Growth hormone receptor antagonists therapy for acromegaly.
Parkinson C; Trainer PJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
[TBL] [Abstract][Full Text] [Related]
25. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
26. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
27. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
29. Pegvisomant. Pharmacia.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2002 May; 3(5):752-7. PubMed ID: 12090548
[TBL] [Abstract][Full Text] [Related]
30. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
31. Treatment strategies for acromegaly.
Roelfsema F; Biermasz NR; Romijn JA; Pereira AM
Expert Opin Emerg Drugs; 2005 Nov; 10(4):875-90. PubMed ID: 16262568
[TBL] [Abstract][Full Text] [Related]
32. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
[TBL] [Abstract][Full Text] [Related]
33. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
[TBL] [Abstract][Full Text] [Related]
34. Discovery and uses of pegvisomant: a growth hormone antagonist.
Berryman DE; Palmer AJ; Gosney ES; Swaminathan S; DeSantis D; Kopchick JJ
Endokrynol Pol; 2007; 58(4):322-9. PubMed ID: 18058724
[TBL] [Abstract][Full Text] [Related]
35. Insights from growth hormone receptor blockade.
Muller AF; van der Lely AJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
[TBL] [Abstract][Full Text] [Related]
36. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
37. Lessons learned from studies with the growth hormone receptor.
Kopchick JJ
Growth Horm IGF Res; 2016 Jun; 28():21-5. PubMed ID: 26216709
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicines in the treatment of acromegaly: focus on pegvisomant.
Roelfsema F; Biermasz NR; Pereira AM; Romijn J
Int J Nanomedicine; 2006; 1(4):385-98. PubMed ID: 17722273
[TBL] [Abstract][Full Text] [Related]
39. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
40. [Growth hormone receptor antagonists: potential indications].
Muller AF; Janssen JA; de Herder WW; van der Lely AJ
Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
